Containing Emulsions, Dispersions, Or Solutions Patents (Class 424/455)
  • Patent number: 11273124
    Abstract: The invention provides functionalized antifungal-loaded liposomal formulations targeting Candida, which minimize damage to healthy human cells, limit antimicrobial exposure, and reduce the development of antifungal resistance.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: March 15, 2022
    Assignee: Brown University
    Inventors: Anita Shukla, Sarah Cowles, Noel Vera-Gonzalez, Christina Bailey-Hytholt, Eli Silvert
  • Patent number: 11197828
    Abstract: The present invention relates to a pharmaceutical composition comprising compound having a log P of at least 5 and a vehicle, wherein the vehicle comprises (a) a fat component in an amount sufficient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: December 14, 2021
    Assignee: SOLURAL PHARMA APS
    Inventor: Bent Højgaard
  • Patent number: 11173169
    Abstract: The patent discloses self-emulsifying formulations of bisphosphonates or bisphosphonic acids in the prevention and treatment of conditions involving calcium or phosphate metabolism. The dosage forms are either capsules, or tablets, or other controlled release drug delivery systems, or devices that contain self-emulsifying formulation of such bisphosphonates or bisphosphonic acids.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: November 16, 2021
    Assignee: Halo Science LLC
    Inventors: Xudong Yuan, Yu Hui, Tian Zhang
  • Patent number: 11154625
    Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: October 26, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS 13
    Inventors: Jean-Baptiste Michel, Didier Letourneur, Frederic Chaubet, Laure Bachelet, Francois Rouzet, Alain Meulemans
  • Patent number: 11090280
    Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: August 17, 2021
    Assignee: PATHEON SOFTGELS INC.
    Inventors: Nachiappan Chidambaram, Aqeel A. Fatmi
  • Patent number: 10959977
    Abstract: The present invention discloses uses of a novel phosphodiesterase 4 (PDE4) inhibitor ZL-n-91 in preparing drugs against lung cancer proliferation and metastasis. The mouse survival curves and in vitro cell experiments show that the PDE4 inhibitor ZL-n-91 can significantly inhibit the proliferation and metastasis of lung cancer cells, indicating that this PDE4 inhibitor ZL-n-91 can become an important target for the studies on anti-lung cancer proliferation and metastasis, to provide a basis for preparing drugs against lung cancer proliferation and metastasis, with promising prospect of development and application.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: March 30, 2021
    Inventors: Allan Zijian Zhao, Sijia Gong, Yan Lin, Fanghong Li, Xiaoxi Li
  • Patent number: 10874619
    Abstract: The present invention relates to new acid resistant hard pharmaceutical capsules, a process for their manufacture and use of such capsules particularly but not exclusively for oral administration of pharmaceuticals, veterinary products, food and dietary supplements to humans or animals. The capsules of the invention are obtained by aqueous compositions comprising a water soluble film forming polymer and gellan gum in a mutual weight ratio of 4 to 15 weight parts of gellan gum for 100 weight parts of film forming polymer.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: December 29, 2020
    Assignee: Capsugel Belgium, NV
    Inventors: Dominique Nicolas Cade, Xiongwei David He
  • Patent number: 10806742
    Abstract: Current krill oil extracts are liquid at room temperature and include only about 45-55% phospholipids. As the purity of phospholipids increases, the extracts become more viscous, making them difficult to handle and process. The invention mixes these pure materials with viscosity-reducing agents to make them amenable to processes such as encapsulation. Thus the invention retains the useful liquid characteristics of known krill extracts while providing much higher concentrations of phospholipids.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: October 20, 2020
    Assignee: Aker BioMarine Antarctic AS
    Inventors: Stefan Hupfeld, Tove Jule Evjen, Finn Myhren, Håvard Thøgersen
  • Patent number: 10736842
    Abstract: Accordingly, the present invention provides a pharmaceutical oil-in-water nano-emulsion, with a pharmaceutically active substance. The selected pharmaceutically active substance is encased in monounsaturated fatty acid droplets with the droplets having an average particle size in the range of 60 to 200 nm. The nano-emulsion is also provided with a non-ionic surfactant system, which is a mixture of polyethers, macrogolglycerides and polysaccharides, along with pharmaceutically acceptable adjuvants. The present invention also provides a process for the preparation of pharmaceutical oil-in-water nano-emulsion.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: August 11, 2020
    Assignee: SYNERGIA BIO SCIENCES PRIVATE LIMITED
    Inventor: Ambikanandan Misra
  • Patent number: 10716836
    Abstract: Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the prevention or delay of loss of residual ?-cell mass, providing a longer remission period and delaying the onset of diabetes related, progressive, complications through immunotherapeutic induction of regulatory T cells specific for human insulin B chain. In addition, the methods described herein can be used to predict whether a subject, e.g., a subject with ongoing anti-insulin autoimmunity, will progress to T1DM, and to evaluate a subject's response to a therapeutic intervention.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: July 21, 2020
    Assignees: Joslin Diabetes Center Inc., Mercia Pharma, Inc.
    Inventors: Tihamer Orban, Peter Blackburn
  • Patent number: 10564140
    Abstract: An in vitro release testing method and system for testing the ability of formulations to deliver agents across a barrier membrane is disclosed. The method may comprise steps of providing a dosage of a semi-solid formulation containing the bioactive agent, a receptor solution, and a barrier membrane to separate the semi-solid formulation and the receptor solution. The receptor solution may be a biphasic solution or an immiscible solution. The semi-solid formulation may be contacted with one side of the barrier membrane and the receptor solution with the other side of the barrier membrane for a time sufficient to produce penetration of the barrier membrane by the semi-solid formulation. The receptor solution may be sampled and assayed to determine the concentration of the bioactive agent in the receptor solution.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: February 18, 2020
    Assignee: BUFFERAD Illinois Inc.
    Inventors: Wen Yang, Kenna Krone, Jerry Z. Zhang, Xiaoyan Xu
  • Patent number: 10525433
    Abstract: A process for preparing nanocapsules having a core-shell structure, comprising: (a) preparing an oil-in-water emulsion by emulsification of an oily phase that comprises a core material, in an aqueous phase, under high shear forces, wherein one or both of the oily phase, and the aqueous phase comprises a sol-gel precursor; (b) subjecting the emulsion obtained in (a) to a high pressure homogenization to obtain a nano-emulsion; and (c) applying conditions for hydrolyzing and polycondensing the sol-gel precursor to obtain nanocapsules having a metal oxide shell encapsulating the core material, said nanocapsules have a particle size distribution of: d10=10-80 nm, d50=30-200 nm, and d90=70-500 nm, in diameter. The invention also relate to nanocapsules having the above particle size distribution and to composition comprising the nanocapsules.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: January 7, 2020
    Assignee: SOL-GEL TECHNOLOGIES LTD.
    Inventors: Ofer Toledano, Hanan Sertchook, Raed Abu-Reziq, Haim Bar-Simantov, Leora Shapiro
  • Patent number: 10500182
    Abstract: A formulation comprising at least one ketogenic source, at least one vitamin, at least one mineral, at least one antioxidant, optionally at least one phytonutrient, and optionally at least one other nutrient, and mixtures and combinations thereof intended for the prevention and mitigation of migraine headache.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: December 10, 2019
    Inventors: Robert Firger, Gerald Haase
  • Patent number: 10420730
    Abstract: A storage stable L-menthol composition including a tablet, caplet, capsule, or sachet dosage form has therein a core containing crystalline L-menthol and at least one pharmaceutical excipient. A proteinaceous coating of a continuous film of proteinaceous material is over the core. The film is effective to substantially prevent the crystalline L-menthol from volatilizing and leaving the core when stored at a temperature of 40 degrees C. and 75% relative humidity from between 1 day to 30 days. The dosage form contains an effective amount of the crystalline L-menthol for treating a gastrointestinal disorder.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: September 24, 2019
    Assignee: Zx Pharma, LLC
    Inventors: Syed M. Shah, Fred Hassan
  • Patent number: 10328022
    Abstract: The subject matter of the present invention is pertinent to the field of vaginal delivery of pharmaceutically active agents. Embodiments of the instant invention disclose methods for treating a variety of progesterone related disorders by vaginal administration of a pullulan capsule comprising one or more antiprogestins.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: June 25, 2019
    Assignee: REPROS THERAPEUTICS INC.
    Inventors: Joseph S. Podolski, Kuang Hsu
  • Patent number: 10314793
    Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: June 11, 2019
    Assignee: Soft Gel Technologies, Inc.
    Inventor: Michael Fantuzzi
  • Patent number: 10166192
    Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: January 1, 2019
    Inventor: Michael Fantuzzi
  • Patent number: 10154967
    Abstract: This invention relates to a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol lipid microsphere preparation having 2,2?,6,6?-tetraisopropyl-4,4?-biphenol as its active ingredient and formed into said lipid microsphere preparation with common medically used injection-grade oil, emulsifier, and injection-grade water.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: December 18, 2018
    Assignee: XI'AN LIBANG PHARMACEUTICAL CO., LTD
    Inventors: Rutao Wang, Tao Chen, Shupan Guo, Huijing Hu, Long An, Weijiao Wang
  • Patent number: 10028925
    Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: July 24, 2018
    Assignee: Patheon Softgels, Inc.
    Inventors: Nachiappan Chidambaram, Aqeel A Fatmi
  • Patent number: 10022344
    Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 17, 2018
    Assignee: Patheon Softgels, Inc.
    Inventors: Nachiappan Chidambaram, Aqeel A. Fatmi
  • Patent number: 10017782
    Abstract: RNA prepared by in vitro transcription using a polymerase chain reaction (PCR)-generated template can be introduced into a cell to modulate cell activity. This method is useful in de-differentiating somatic cells to pluripotent, multipotent, or unipotent cells; re-differentiating stem cells into differentiated cells; or reprogramming of somatic cells to modulate cell activities such as metabolism. Cells can also be transfected with inhibitory RNAs, such as small interfering RNA (siRNA) or micro RNA (miRNA), or combinations thereof to induce reprogramming of somatic cells. For example, target cells are isolated from a donor, contacted with one or more RNA's causing the cells to be de-differentiated, re-differentiated, or reprogrammed in vitro, and administered to a patient in need thereof. The resulting cells are useful for treating one or more symptoms of a variety of diseases and disorders, for organ regeneration, and for restoration of the immune system.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: July 10, 2018
    Assignee: Yale University
    Inventors: Peter M. Rabinovich, Sherman M. Weissman, Erkut Bahceci, Marina E. Komarovskaya
  • Patent number: 10004693
    Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: June 26, 2018
    Assignee: Flamel Ireland Limited
    Inventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
  • Patent number: 9895367
    Abstract: An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal fluid. The invention also relates to a process for the preparation of oral solution containing NRC-AN-019 in an effective concentration for the better therapy against Chronic Myeloid Leukemia as BCR-ABL tyrosine kinase inhibitor and against other tumors such as head and neck cancer, prostate cancer and the like.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: February 20, 2018
    Assignee: NATCO PHARMA LIMITED
    Inventors: Durga Maheswari Parvataneni, Siddhartha Yedluri, Venkata Satyanarayana Appadwedula, Kali Satya Bhujanga Rao, Venkaiah Chowdary Nannapaneni
  • Patent number: 9848617
    Abstract: Provided is a coagulant composition for tofu having a sufficient slow-acting property in coagulation of soymilk in a tofu production process as a necessary condition, and being capable of developing the original flavor of tofu originated in a raw material soybean and its pressed soymilk as a sufficient condition, the coagulant composition being obtained by dispersing an inorganic salt-based coagulant for tofu in a mixture of a natural wax and an edible oil or fat.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: December 26, 2017
    Assignee: TAIKI PRODUCT, INC.
    Inventors: Kenzou Kanai, Yukitaka Tanaka
  • Patent number: 9802984
    Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, an isolated peptide comprising the amino acid sequence LRRFSTAPFAFIDINDVINF, which exhibits anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models is disclosed. The isolate peptide also exhibits anti-lymphangiogenic and directly anti-tumorigenic properties.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: October 31, 2017
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Aleksander S. Popel, Niranjan B. Pandey, Esak Lee, Jordan J. Green, Ron B. Shmueli
  • Patent number: 9693978
    Abstract: Liquid and semi-solid pharmaceutical compositions, which can be administered in liquid form or can be used for preparing capsules, are described herein. The composition comprises the salt of one ore more active agents, polyethylene glycol, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of active agent, and water. The pH of the composition is adjusted within the range of 2.5-7.5. The de-ionizing agent causes partial de-ionization (neutralization) of the salt of the active agent resulting in enhanced bioavailability of salts of weakly acidic, basic or amphoteric active agents as well as lesser amounts of polyethylene glycol (PEG) esters.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: July 4, 2017
    Assignee: Banner Life Sciences LLC
    Inventors: Nachiappan Chidambaram, Aqeel Fatmi
  • Patent number: 9693979
    Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: July 4, 2017
    Assignee: Banner Life Sciences LLC
    Inventors: Nachiappan Chidambaram, Aqeel A Fatmi
  • Patent number: 9687496
    Abstract: It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addition it is provided a method for preparing the pharmaceutical composition.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: June 27, 2017
    Assignee: ASARINA PHARMA AB
    Inventors: Torbjörn Bäckström, Anders Carlsson
  • Patent number: 9592296
    Abstract: The invention relates to a pharmaceutical composition for oral administration comprising or consisting of (i) 10 to 30% weight, of at least one pharmaceutically active substance selected from the group consisting of water-soluble, oxidatively-degradable statins, preferably atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin or a combination thereof, (ii) 0.01 to 3% weight, of a first anti-oxidatively active substance (A1), (iii) 0.01 to 3% weight, of a second anti-oxidatively active substance (A2) that differs from the first anti-oxidatively active substance (A1), and (iv) 60 to 85% weight of at least one additive, selected from the group consisting of filler, binder, flow-regulating agent, disintegrant and anti-blocking agent or a combination thereof, and the use of the pharmaceutical composition in medicine.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: March 14, 2017
    Assignee: HEXAL AG
    Inventors: Theresa Taeubrich, Patrick Rother
  • Patent number: 9572894
    Abstract: The present invention provides three-component compositions comprising microparticles, a tumor antigen, a first immune adjuvant, and a second immune adjuvant. Also provided are chemo-immunotherapeutic compositions comprising microparticles, a chemotherapeutic agent, and an immune adjuvant.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: February 21, 2017
    Assignee: The University of Iowa Research Foundation
    Inventors: Aliasger K. Salem, Sean M. Geary, George J. Weiner, Caitlin Lemke, Yogita Krishnamachari
  • Patent number: 9555003
    Abstract: Provided is an oral solid preparation of a compound anti-tubercular drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. The compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not come to contact with each other directly. The compound oral solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: January 31, 2017
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Maojian Gu, Qilan Zheng, Chao Xu, Ning Li, Guixian Chen, Lan Zheng, Min Wang, Lintao Jiang
  • Patent number: 9468602
    Abstract: The present invention refers to a microemulsion formulation suitable for preventing assembly of amphiphilic drug molecules which may cause hypersensitivity reactions and other unwanted side effects.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: October 18, 2016
    Assignee: AZAD Pharma AG
    Inventors: Fabio Carli, Elisabetta Chiellini, Van Van Khov-Tran, Mihran Baronian
  • Patent number: 9314435
    Abstract: The invention discloses stable formulations of acetylsalicylic acid or salts thereof, omega-3 fatty acids and amylose in soft gelatin capsules.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: April 19, 2016
    Assignee: ALTERGON S.A.
    Inventors: Simone Carucci, Alberto Bernareggi, Maurizio Marchiorri, Marco Pontiggia
  • Patent number: 9314441
    Abstract: A bi-phasic pharmaceutical composition for oral administration including one or more solid active ingredient containing particles dispersed within a semi-solid carrier formulation. The solid particles include a coating with pH-triggered drug release properties and the semi-solid carrier formulation is formulated at a pH that is different than the pH at which the active ingredient release properties of the coating are triggered. Also described is a delivery system for delivery of the bi-phasic pharmaceutical composition including the bi-phasic pharmaceutical composition described above and a dispenser pouch formed from flexible laminate sheets. Further, a process for manufacturing the two-phase pharmaceutical delivery system is described including the filling the bi-phasic pharmaceutical composition into flexible dispenser pouches, which allows the patient to squeeze and dispense the contents of the package directly into the oral cavity.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: April 19, 2016
    Assignee: R.P. Scherer Technologies, LLC
    Inventor: Hans Jürgen Maier
  • Patent number: 9278077
    Abstract: The presently claimed and disclosed inventive concept(s) contemplates a novel polymeric oral dosage form (transmucosal delivery vehicle) for delivery of pharmaceutical and nutriceutical bioactive agents to the mucosa and bloodstream of the intestine. The oral dosage form of the presently claimed and disclosed inventive concept(s) comprises a polymeric coating which encapsulates the bioactive agent and inhibits degradation and dissolution of the bioactive agent within the stomach and within the lumen of the intestine until after passing through the mucosal wall of the small and/or large intestine. The enzymatic degradation of the polymeric delivery vehicle containing the bioactive agent is substantially inhibited until after absorption of the polymeric delivery vehicle into blood vessels of the intestinal mucosa.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: March 8, 2016
    Assignee: TAMARISK TECHNOLOGIES GROUP, LLC
    Inventor: Daniel R. DeBrouse
  • Patent number: 9205044
    Abstract: An aqueous pharmaceutical preparation for administration of a slightly soluble PDE4 inhibitor is described.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: December 8, 2015
    Assignee: TAKEDA GMBH
    Inventor: Rudolf Linder
  • Patent number: 9192896
    Abstract: A method for producing a product comprising at least one selected from C2+ hydrocarbons, oxygenates, and combinations thereof from light gas comprising one or more of carbon dioxide, methane, ethane, propane, butane, pentane, and methanol by forming a dispersion of light gas in a liquid feed, wherein the dispersion is formed at least in part with high shear forces and wherein at least one of the liquid feed and the light gas is a hydrogen source. A system for carrying out the method is also presented.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: November 24, 2015
    Assignee: H R D Corporation
    Inventors: Abbas Hassan, Ebrahim Bagherzadeh, Rayford G. Anthony, Gregory Borsinger, Aziz Hassan
  • Patent number: 9060927
    Abstract: Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid or sodium citrate. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection. In the preferred embodiment, the insulin is provided as a clear liquid, neutral pH, in a multi-use sterile vial. In an alternative embodiment, the insulin is provided as a powder in a sterile vial.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: June 23, 2015
    Assignee: Biodel Inc.
    Inventors: Solomon S. Steiner, Roderike Pohl, Ming Li, Robert Hauser
  • Patent number: 9056088
    Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: June 16, 2015
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 9034375
    Abstract: A water-in-oil emulsion composition which contains a low water-solubility but oil-soluble ultraviolet absorber, and which exhibits excellent ultraviolet light protection and stability. The composition contains (a) an aqueous dispersion of an oil-soluble ultraviolet absorber; (b) a polyoxyalkylene-modified polysiloxane having a molecular mass of at least 2000; and (c) at most 5 mass % of an ultraviolet scattering agent; and component (a) being contained in the internal phase. Component (a) is preferably an aqueous dispersion of a complex particle of an oil-soluble ultraviolet absorber and an organic polymer.
    Type: Grant
    Filed: April 11, 2011
    Date of Patent: May 19, 2015
    Assignee: SHISEIDO COMPANY, LTD.
    Inventors: Yuko Nagare, Kazuhiro Yamaguchi
  • Patent number: 9023387
    Abstract: The present invention is directed to a transfer resistant and long wear composition containing: (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) water; (d) at least one volatile solvent; (e) at least one non-volatile solvent capable of solubilizing the oil-soluble polar modified polymer; (e) at least one surfactant; and (f) at least one colorant.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: May 5, 2015
    Assignee: L'Oreal
    Inventors: Hy Si Bui, Mohamed Kanji, Susan Halpern, Christine Chen
  • Patent number: 9023386
    Abstract: The present invention provides microspheres comprising a plurality of nanocapsules accommodated in a gel forming polymer, the plurality of nanocapsules comprising an oil core carrying a non hydrophilic active agent and a shell of polymeric coating. The invention also provides a method for preparing the microspheres of the invention, pharmaceutical compositions comprising the same as well as methods of use of the microspheres, specifically, in therapeutic, cosmetic and diagnostic applications.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: May 5, 2015
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Shimon Benita, Alona Rom, Taher Nasser
  • Patent number: 9017720
    Abstract: The present invention is directed to seamless capsules and methods for making seamless capsules having a high oil content as described herein. More specifically, the present invention is directed to seamless capsules, and methods for making seamless capsules, made from a process involving the steps of: (a) preparing an emulsion comprising oil, water, an emulsifier, and at least one of a water-soluble monovalent metal salt, polyvalent metal salt, and an acid, wherein said oil is present in an amount of at least 50% by weight of said emulsion; with the proviso that said emulsion does not contain marmelo mucilage; and (b) adding portions of said emulsion to an aqueous gelling bath comprised of at least one ionic polysaccharide thereby encapsulating said portions of said emulsion in a polysaccharide gel membrane, and optionally (c) drying the resulting capsules by removing water.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: April 28, 2015
    Assignee: FMC Bioploymer AS
    Inventors: Peder Oscar Andersen, Olav Gåseröd, Christian Klein Larsen
  • Patent number: 9000048
    Abstract: The present invention provides therapeutic formulations, including therapeutic emulsions and nanoemulsions, and related methods for the delivery of fluorinated therapeutic compounds, including an important class of low boiling point perfluorinated and/or perhalogenated volatile anesthetics. Emulsion-based fluorinated volatile anesthetic formulations compatible with intravenous administration are provided that are capable of delivering and releasing amounts of fluorinated volatile anesthetic compounds effective for inducing and maintaining anesthesia in patients. Intravenous delivery of the present emulsion-based fluorinated volatile anesthetic formulations permits anesthetic levels in a patient to be selectively adjusted very rapidly and accurately without the need to hyperventilate patients and without the use of irritating agents.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: April 7, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Sandro Mecozzi, Robert A. Pearce, Jonathan P. Fast
  • Publication number: 20150079164
    Abstract: The present disclosure relates to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with acne and/or eczema (dermatitis).
    Type: Application
    Filed: March 15, 2013
    Publication date: March 19, 2015
    Applicant: Pronova Biopharma Norge AS
    Inventors: David A. Fraser, Alexis Garras
  • Patent number: 8974820
    Abstract: The invention provides an apparatus for producing soft gel capsules having encapsulated therein microparticles, nanoparticles and fluids, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies; (d) a liquid fill system (medicine pump system); (e) a wedge for heating gelatine ribbons and feeding said fill; and (f) one or more microgranule or nanogranule feeders located on each side of the rotary dies, said feeders being synchronized to rotate at the same tangential speed as the rotary dies.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: March 10, 2015
    Assignee: Procaps SAS
    Inventors: Carlos Salazar Altamar, Gustavo Anaya, Braulio Teran, Newman Aguas Navarro, Willmer Herrera
  • Patent number: 8968775
    Abstract: Provided are pharmaceutical carriers based on oil-in-water microemulsions and methods of making same. Also provided are pharmaceutical compositions comprising a carrier of the invention and a lipophilic active pharmaceutical ingredient (API), as well as methods for making same. The pharmaceutical compositions are particularly suitable for use in formulating lipophilic APIs for topical administration to the eye. Specifically included are pharmaceutical compositions comprising fenofibrate or fenofibric acid as API. Also provided is a method of treating a disease of the posterior segment of the eye. Also provided is a pharmaceutical composition comprising a compound represented by formulated for topical administration to the eye.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 3, 2015
    Assignee: EyeCRO, LLC
    Inventors: Ronald A. Wassel, Fadee G. Mondalek, Rafal A. Farjo, Alexander B. Quiambao, Didier J. Nuño
  • Publication number: 20150017238
    Abstract: Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.
    Type: Application
    Filed: January 3, 2013
    Publication date: January 15, 2015
    Applicant: Oramed, Ltd.
    Inventor: Miriam Kidron
  • Patent number: 8916204
    Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 23, 2014
    Assignee: Abraxis BioSciences, LLC
    Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
  • Patent number: 8911777
    Abstract: An oral tacrolimus composition comprises minicapsules having a core containing tacrolimus in a solubilized liquid form. The minicapsules have a release profile to release the pre-solubilized tacrolimus throughout the entire gastrointestinal tract. The composition may be used, for example, for treatment or prevention of solid organ transplant rejection.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: December 16, 2014
    Assignee: Sigmoid Pharma Limited
    Inventor: Ivan Coulter